Methylprednisolone: uses, dosing, side effects & brands

How methylprednisolone is dosed

From the FDA label for Methylprednisolone (application ANDA040232). Other methylprednisolone products — different forms, different strengths — are dosed differently. Follow the label for the one you were prescribed.

The initial dosage of methylprednisolone tablets may vary from 4 mg to 48 mg of methylprednisolone per day depending on the specific disease entity being treated. In situations of less severity lower doses will generally suffice while in selected patients higher initial doses may be required. The initial dosage should be maintained or adjusted until a satisfactory response is noted. If after a reasonable period of time there is a lack of satisfactory clinical response, methylprednisolone should be discontinued and the patient transferred to other appropriate therapy. IT SHOULD BE EMPHASIZED THAT DOSAGE REQUIREMENTS ARE VARIABLE AND MUST BE INDIVIDUALIZED ON THE BASIS OF THE DISEASE UNDER TREATMENT AND THE RESPONSE OF THE PATIENT. After a favorable response is noted, the proper maintenance dosage should be determined by decreasing the initial drug dosage in small decrements at appropriate time intervals until the lowest dosage which will maintain an adequate clinical response is reached. It should be kept in mind that constant monitoring is needed in regard to drug dosage. Included in the situations which may make dosage adjustments necessary are changes in clinical status secondary to remissions or exacerbations in the disease process, the patient's individual drug responsiveness, and the effect of patient exposure to stressful situations not directly related to the disease…

Methylprednisolone side effects

Fluid and Electrolyte Disturbances • Sodium retention • Congestive heart failure in susceptible patients • Hypertension • Fluid retention • Potassium loss • Hypokalemic alkalosis Musculoskeletal • Muscle weakness • Loss of muscle mass • Steroid myopathy • Osteoporosis • Tendon rupture, particularly of the Achilles tendon • Vertebral compression fractures • Aseptic necrosis of femoral and humeral heads • Pathologic fracture of long bones Gastrointestinal • Peptic ulcer with possible perforation and hemorrhage • Pancreatitis • Abdominal distention • Ulcerative esophagitis Increases in alanine transaminase (ALT, SGPT), aspartate transaminase (AST, SGOT), and alkaline phosphatase have been observed following corticosteroid treatment. These changes are usually small, not associated with any clinical syndrome and are reversible upon discontinuation. Dermatologic • Impaired wound healing • Petechiae and ecchymoses • May suppress reactions to skin tests • Thin fragile skin • Facial erythema • Increased sweating Neurological • Increased intracranial pressure with papilledema (pseudo-tumor cerebri) usually after treatment • Convulsions • Vertigo • Headache Endocrine • Development of Cushingoid state • Suppression of growth in children • Secondary adrenocortical and pituitary unresponsiveness, particularly in times of stress, as in trauma, surgery or illness • Menstrual irregularities •…

Every methylprednisolone product we track (7)

Same active ingredient — different manufacturer, form, price and FDA recall record. That last one is what our independent score measures.

What methylprednisolone pills look like

Imprint codes, colour and shape from the FDA’s labelling data. Match the imprint on your pill — or search any imprint.

Methylprednisolone recalls

From the FDA Enforcement database. A recall covers specific lots — not the drug as a whole.

• methylprednisolone tablets

  Labeling: Not Elsewhere Classified. Incorrect orientation of the blister foil applied to the blister cavities, which results in incorrect dosing information when following the directions on the foil.

  Greenstone Llc · Jan 15, 2026

• MethylPREDNISolone Acetate Injectable Suspension

  Presence of Particulate Matter: Potential for black particulates in the drug product.

  Sagent Pharmaceuticals · Apr 25, 2024

• Methylprednisolone acetate Injectable Suspension

  Failed Dissolution Specifications

  Eugia US LLC · Feb 20, 2024